Identification of a chromatin regulator signature for predicting prognosis of prostate cancer patient

OBJECTIVE: Prostate cancer is a malignancy with unsatisfactory prognosis. Mounting proofs have verified that chromatin regulators (CRs) participate in the developmental process of tumor. Hence, this research intended to reveal the biofunction and prognosis significance of CRs in prostate cancer patients. MATERIALS AND METHODS: CRs were obtained from previously finished topic research. The mRNA expression and clinical data were acquired from TCGA and GEO datasets. Molecular subtypes were identified by ConsensusClusterPlus package. Cox regressive analyses, LASSO regressive analyses and stepAIC were utilized to screen the prognosis-related genes and establish the risk model for forecasting outcomes in prostate cancer. Genomic variation, immune infiltration, drug sensitivity difference and analysis of clinical features were all investigated. RESULTS: 462 samples in TCGA cohort study were classified into two clusters base on 23 prognosis CRs. Patients in cluster 1 (clust1) presented better overall survival (OS), lower tumor mutation burden (TMB), enhanced immune infiltration, higher immune escape and hyposensitivity to several drugs. Furthermore, our team smoothly established and substantiated a 10 CR-derived model for forecasting the prognostic results of individuals with prostate cancer, which was an independent prognosis indicator. Functional analyses revealed that CRs were predominantly enriched in tumor-associated signal paths. The CR-derived model was related to immunocyte infiltration and sensitive to several drugs. CONCLUSIONS: Holistically, the present research offered fresh enlightenment regarding the biofunction of CRs in prostate cancer. Our team discovered a dependable prognosis marker for the survival of individuals with prostate cancer.